A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab
Matteo Megna,* Angelo Ruggiero,* Antonia Salsano, Giuseppe Lauletta, Antonio Portarapillo, Ginevra Torta, Fabrizio Martora, Luca Potestio Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy*These authors contrib...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2023-12-01
|
| Series: | Clinical, Cosmetic and Investigational Dermatology |
| Subjects: | |
| Online Access: | https://www.dovepress.com/a-case-of-erythrodermic-psoriasis-successfully-treated-with-risankizum-peer-reviewed-fulltext-article-CCID |
| _version_ | 1797403916752650240 |
|---|---|
| author | Megna M Ruggiero A Salsano A Lauletta G Portarapillo A Torta G Martora F Potestio L |
| author_facet | Megna M Ruggiero A Salsano A Lauletta G Portarapillo A Torta G Martora F Potestio L |
| author_sort | Megna M |
| collection | DOAJ |
| description | Matteo Megna,* Angelo Ruggiero,* Antonia Salsano, Giuseppe Lauletta, Antonio Portarapillo, Ginevra Torta, Fabrizio Martora, Luca Potestio Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy*These authors contributed equally to this workCorrespondence: Luca Potestio, Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini, 5, Naples, 80131, Italy, Tel +39 - 081 -7462457, Fax +39 - 081 - 7462442, Email potestioluca@gmail.comAbstract: Psoriasis is a chronic inflammatory cutaneous disease, affecting up to 3% of the worldwide population. Several clinical phenotypes can be distinguished. Among these, erythrodermic psoriasis (EP) is a rare and severe variant (less than 3% of cases), characterized by severe generalized erythema and scaling affecting at least 90% of the body surface area. EP is often a life-threatening condition, since several systemic symptoms (tachycardia, fever, fatigue, lymphadenopathy, dehydration, serum electrolyte disturbances) can be associated. Thus, a prompt and appropriate treatment is mandatory. Unfortunately, EP treatment is challenging. Indeed, the reduced prevalence of EP makes clinical trials feasibility difficult, leading to the absence of established guidelines. So, the treatment of EP is often derived from moderate-to-severe psoriasis management which relies on the use of conventional systemic drugs (cyclosporine, dimethyl fumarate, methotrexate, retinoids) and biologic agents. However, conventional systemic drugs are often contraindicated for patients’ comorbidities, or their use is characterized by reduced efficacy and various adverse events (AEs). The recent development of biologic drugs, which showed excellent results in terms of effectiveness and safety in plaque psoriasis, made these drugs an ideal weapon in EP management, despite their use in EP is still off-label. Among these, risankizumab, a humanized immunoglobulin G1 monoclonal antibody targeting the p19 subunit of the IL23, is one of the latest biologics approved for the management of moderate-to-severe psoriasis. Herein, we reported the first case of a caucasian patient affected by EP successfully treated with risankizumab, reaching PASI100 response after 16 weeks of treatment, without experiencing AEs.Keywords: erythrodermic psoriasis, treatment, risankizumab |
| first_indexed | 2024-03-09T02:45:31Z |
| format | Article |
| id | doaj.art-8def8a25e6574a299f11200485211399 |
| institution | Directory Open Access Journal |
| issn | 1178-7015 |
| language | English |
| last_indexed | 2024-03-09T02:45:31Z |
| publishDate | 2023-12-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Clinical, Cosmetic and Investigational Dermatology |
| spelling | doaj.art-8def8a25e6574a299f112004852113992023-12-05T17:06:54ZengDove Medical PressClinical, Cosmetic and Investigational Dermatology1178-70152023-12-01Volume 163503350788737A Case of Erythrodermic Psoriasis Successfully Treated with RisankizumabMegna MRuggiero ASalsano ALauletta GPortarapillo ATorta GMartora FPotestio LMatteo Megna,* Angelo Ruggiero,* Antonia Salsano, Giuseppe Lauletta, Antonio Portarapillo, Ginevra Torta, Fabrizio Martora, Luca Potestio Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy*These authors contributed equally to this workCorrespondence: Luca Potestio, Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini, 5, Naples, 80131, Italy, Tel +39 - 081 -7462457, Fax +39 - 081 - 7462442, Email potestioluca@gmail.comAbstract: Psoriasis is a chronic inflammatory cutaneous disease, affecting up to 3% of the worldwide population. Several clinical phenotypes can be distinguished. Among these, erythrodermic psoriasis (EP) is a rare and severe variant (less than 3% of cases), characterized by severe generalized erythema and scaling affecting at least 90% of the body surface area. EP is often a life-threatening condition, since several systemic symptoms (tachycardia, fever, fatigue, lymphadenopathy, dehydration, serum electrolyte disturbances) can be associated. Thus, a prompt and appropriate treatment is mandatory. Unfortunately, EP treatment is challenging. Indeed, the reduced prevalence of EP makes clinical trials feasibility difficult, leading to the absence of established guidelines. So, the treatment of EP is often derived from moderate-to-severe psoriasis management which relies on the use of conventional systemic drugs (cyclosporine, dimethyl fumarate, methotrexate, retinoids) and biologic agents. However, conventional systemic drugs are often contraindicated for patients’ comorbidities, or their use is characterized by reduced efficacy and various adverse events (AEs). The recent development of biologic drugs, which showed excellent results in terms of effectiveness and safety in plaque psoriasis, made these drugs an ideal weapon in EP management, despite their use in EP is still off-label. Among these, risankizumab, a humanized immunoglobulin G1 monoclonal antibody targeting the p19 subunit of the IL23, is one of the latest biologics approved for the management of moderate-to-severe psoriasis. Herein, we reported the first case of a caucasian patient affected by EP successfully treated with risankizumab, reaching PASI100 response after 16 weeks of treatment, without experiencing AEs.Keywords: erythrodermic psoriasis, treatment, risankizumabhttps://www.dovepress.com/a-case-of-erythrodermic-psoriasis-successfully-treated-with-risankizum-peer-reviewed-fulltext-article-CCIDerythrodermic psoriasistreatmentrisankizumab |
| spellingShingle | Megna M Ruggiero A Salsano A Lauletta G Portarapillo A Torta G Martora F Potestio L A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab Clinical, Cosmetic and Investigational Dermatology erythrodermic psoriasis treatment risankizumab |
| title | A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab |
| title_full | A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab |
| title_fullStr | A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab |
| title_full_unstemmed | A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab |
| title_short | A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab |
| title_sort | case of erythrodermic psoriasis successfully treated with risankizumab |
| topic | erythrodermic psoriasis treatment risankizumab |
| url | https://www.dovepress.com/a-case-of-erythrodermic-psoriasis-successfully-treated-with-risankizum-peer-reviewed-fulltext-article-CCID |
| work_keys_str_mv | AT megnam acaseoferythrodermicpsoriasissuccessfullytreatedwithrisankizumab AT ruggieroa acaseoferythrodermicpsoriasissuccessfullytreatedwithrisankizumab AT salsanoa acaseoferythrodermicpsoriasissuccessfullytreatedwithrisankizumab AT laulettag acaseoferythrodermicpsoriasissuccessfullytreatedwithrisankizumab AT portarapilloa acaseoferythrodermicpsoriasissuccessfullytreatedwithrisankizumab AT tortag acaseoferythrodermicpsoriasissuccessfullytreatedwithrisankizumab AT martoraf acaseoferythrodermicpsoriasissuccessfullytreatedwithrisankizumab AT potestiol acaseoferythrodermicpsoriasissuccessfullytreatedwithrisankizumab AT megnam caseoferythrodermicpsoriasissuccessfullytreatedwithrisankizumab AT ruggieroa caseoferythrodermicpsoriasissuccessfullytreatedwithrisankizumab AT salsanoa caseoferythrodermicpsoriasissuccessfullytreatedwithrisankizumab AT laulettag caseoferythrodermicpsoriasissuccessfullytreatedwithrisankizumab AT portarapilloa caseoferythrodermicpsoriasissuccessfullytreatedwithrisankizumab AT tortag caseoferythrodermicpsoriasissuccessfullytreatedwithrisankizumab AT martoraf caseoferythrodermicpsoriasissuccessfullytreatedwithrisankizumab AT potestiol caseoferythrodermicpsoriasissuccessfullytreatedwithrisankizumab |